Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted therapy for high-risk Hodgkin lymphoma in children (AHOD0831)
NCT01026220Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Dec 2009
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of ifosfamide, vinorelbine in Hodgkin lymphoma (HL), sponsored by Children's Oncology Group. Started Dec 2009; status: completed.
02
Drugs
ifosfamidevinorelbine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01026220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01026220.